Target Information

Target General Infomation
Target ID
T86682
Target Name
Jun N terminal kinase
Target Type
Clinical Trial
Disease Cancer [ICD9: 140-229; ICD10: C00-C96]
Idiopathic pulmonary fibrosis; Discoid lupus erythematosus [ICD9:516.3, 695.4; ICD10: J84.1, L93.0]
Neurological disease [ICD9: 338, 338.2, 410, 782.3,780; ICD10: I21, I22, R52, R52.1-R52.2, R60.9, G89]
BioChemical Class
Transferases (EC:2)
EC Number
EC 2.7.11.24
Drugs and Mode of Action
Drug(s) AM-111 Drug Info Phase 3 Neurological disease [524909]
CC-401 Drug Info Phase 2 Cancer [531693]
CC-930 Drug Info Phase 2 Idiopathic pulmonary fibrosis; Discoid lupus erythematosus [523174], [523684]
Modulator AM-111 Drug Info
CC-401 Drug Info
CC-930 Drug Info [533058]
References
Ref 523174ClinicalTrials.gov (NCT01203943) A Study to Characterize the Safety, PK and Biological Activity of CC-930 in Idiopathic Pulmonary Fibrosis (IPF). U.S. National Institutes of Health.
Ref 523684ClinicalTrials.gov (NCT01466725) A Research Study to Assess if CC-930 is Safe in Treating Subjects With Discoid Lupus Erythematosus. U.S. National Institutes of Health.
Ref 524909ClinicalTrials.gov (NCT02235272) Efficacy and Safety of XG-102 in Reduction of Post-cataract Surgery Intraocular Inflammation. U.S. National Institutes of Health.
Ref 531693SP600125 inhibits Orthopoxviruses replication in a JNK1/2 -independent manner: Implication as a potential antipoxviral. Antiviral Res. 2012 Jan;93(1):69-77.
Ref 533058In vitro metabolism of a novel JNK inhibitor tanzisertib: interspecies differences in oxido-reduction and characterization of enzymes involved in metabolism. Xenobiotica. 2015;45(6):465-80.

If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.